Skip to content

Kyverna Therapeutics, Inc. KYTX Non Cash Interest Expense

Non Cash Interest Expense at other companies

Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$39K+14.7%
Cerus logo
CerusCERS
$98K0.0%
Novanta logo
NovantaNOVT
$368K+26.7%
Porch Group, Inc. logo
Porch Group, Inc.PRCH
$14.86M+31.1%
Disc Medicine logo
Disc MedicineIRON
$206K-0.5%
Laureate Education, Inc. logo
Laureate Education, Inc.LAUR
$593K+56.1%

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$498.52M+276%
Enterprise value$475.49M+475%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0.0×
Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept kytx:NonCashInterestExpense.

The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kyverna Therapeutics, Inc.'s non cash interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kyverna Therapeutics, Inc.'s non cash interest expense?
Kyverna Therapeutics, Inc. (KYTX) reported non cash interest expense of $114K in Q1 2026.
What does non cash interest expense mean?
This reflects interest-related expenses that are recognized in the income statement but do not result in a cash outflow during the period, such as the amortization of debt issuance costs or original issue discounts. It is added back to net income to reconcile to operating cash flow. This metric helps distinguish between the company's actual cash interest burden and its total accounting interest expense.